Outcome of the meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e Thursday,13th November 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Welcure Drugs & Pharmaceuticals approved the unaudited financial results for the quarter and half year ended 30 September 2025. Revenue from operations surged to Rs 6,562.38 lakh in Q2 FY26 (vs Rs 2,455 lakh in Q2 FY25), with H1 FY26 revenue at Rs 36,553.83 lakh versus Rs 2,455 lakh in H1 FY25. Net profit for H1 FY26 stood at Rs 3,180.41 lakh. Segmental reporting shows the company is now deriving its revenue entirely from a new 'Agriculture' segment, with zero contribution from drugs and pharmaceuticals. Total assets ballooned to Rs 63,289.06 lakh, driven mainly by a massive jump in trade receivables to Rs 38,448.83 lakh (from Rs 1,895 lakh). The statutory auditor issued a Disclaimer of Opinion citing absence of supporting documents for sales, purchases, inventory valuation, unconfirmed trade receivables and advances, no Fixed Asset register, no MSME creditor classification, and unsecured loans without agreements. Management stated it cannot estimate the impact due to lack of records and proper handover from the previous management. This is a repetitive qualification.
The Disclaimer of Opinion is a serious red flag — the auditor could not verify the authenticity of the bulk of the reported numbers, particularly the sharp revenue jump and ballooning receivables. Shareholders and potential investors should treat the Q2/H1 numbers with extreme caution, as the actual financial position could be materially different once records are reconciled. Negative stock-price sentiment is likely, especially given the unexplained segment shift from pharma to agriculture.